This first graphic shows the first tranche of medications selected for price negotiation in 2024, for implementation in the 2026 Part D formularies. Also note the percentage price reductions. Specific pricing for meds will depend on the particular Part D drug plan selected by the member.
This second graphic of selected medications for price negotiation::
The third tranche of drugs have been selected for price negotiation. Results should be available in about August 2026. Here is the list form the CMS press release::
CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation
| Anoro Ellipta | GlaxoSmithKline Intellectual Property Development Ltd. England |
| Biktarvy | Gilead Sciences Inc |
| Botox; Botox Cosmetic | AbbVie Inc. |
| Cimzia | UCB, Inc. |
| Cosentyx | Novartis Pharmaceuticals Corporation |
| Entyvio | Takeda Pharmaceuticals U.S.A., Inc. |
| Erleada | Janssen Biotech, Inc. |
| Kisqali | Novartis Pharmaceuticals Corporation |
| Lenvima | Eisai Inc |
| Orencia | Bristol-Myers Squibb Company |
| Rexulti | Otsuka Pharmaceutical Company, Ltd. |
| Tradjenta1 | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Trulicity | Eli Lilly and Company |
| Verzenio | Eli Lilly and Company |
| Xeljanz; Xeljanz XR | PF PRISM CV |
| Xolair | Genentech, Inc. |
- This drug was selected for renegotiation for the third cycle of negotiations in the Negotiation Program.
Key Milestones to Date
On January 27, 2026, CMS announced the 15 drugs payable under Medicare Part B and/or covered under Medicare Part D selected for the third cycle of negotiations.
On March 13, 2026, CMS announced the drug companies that manufacture the 15 drugs selected for the Negotiation Program that have chosen to participate in the third cycle of the Negotiation program, along with the drug company that manufactures the one drug selected for renegotiation.
CMS sends an initial offer for each selected drug for which the drug company is participating in the Negotiation Program with CMS’ proposal for the maximum fair price and concise justification no later than June 1, 2026. The drug company will have 30 days to respond to the initial offer by accepting the offer or providing a counteroffer, if desired.
Get CMS news at cms.gov/newsroom, sign up for CMS news via email and follow CMS on X @CMSgov